文献速递炎症性肠病

停用免疫调节剂与抗TNF治疗中炎症性肠病应答丢失无关

Immunomodulator Withdrawal From Anti-TNF Therapy Is Not Associated With Loss of Response in Inflammatory Bowel Disease.
PubMed 文献 · Clin Gastroenterol Hepatol · 2022-01-31

这项回顾性队列研究纳入614个联合治疗疗程(543例炎症性肠病患者),比较停用免疫调节剂与继续联合治疗的结果。停用免疫调节剂与应答丢失风险升高无关(aHR 1.08;95%CI 0.72-1.61),但抗药抗体检出更频繁(aHR 2.14;95%CI 1.17-3.94)。作者认为需前瞻性随机对照试验验证。

要点

  • 停用免疫调节剂后应答丢失风险未显著升高(aHR 1.08;95%CI 0.72-1.61)。
  • 停用免疫调节剂后抗药抗体检出更频繁(aHR 2.14;95%CI 1.17-3.94)。
  • 停用时临床缓解降低应答丢失风险(aHR 0.48;95%CI 0.25-0.93)。

核心结论

  • 在该回顾性队列中,停用免疫调节剂的患者在随后1-2年内应答丢失风险未增加,但观察到抗药抗体增加。
  • 作者认为该发现需前瞻性验证,最好通过有足够把握度的随机对照试验。

研究设计与样本

  • 回顾性队列研究,在综合医院和三级转诊中心开展。
  • 纳入2011年1月1日至2019年1月1日期间接受抗TNF治疗≥4个月且基线联用免疫调节剂的成人炎症性肠病患者。
  • 共纳入543例患者的614个联合治疗疗程,随访1664患者年。

主要发现

  • 296个(48.2%)疗程在中位0.9年(四分位距0.6-2.1年)后停用免疫调节剂。
  • 停用免疫调节剂与应答丢失风险升高无关(aHR 1.08;95%CI 0.72-1.61)。
  • 停用免疫调节剂后抗药抗体检出更频繁(aHR 2.14;95%CI 1.17-3.94)。
  • 停用时临床缓解降低应答丢失风险(aHR 0.48;95%CI 0.25-0.93)。
  • 停用前联合治疗时间更长降低抗药抗体风险(每年HR 0.56;95%CI 0.32-0.91)。

关键数值与推荐

  • 主要终点为应答丢失(即因疾病活动停用抗TNF)和抗药抗体。
  • 采用混合效应Cox回归分析计算校正风险比(aHR)。
  • 停用免疫调节剂后英夫利昔单抗谷浓度较低(P=0.01)。
  • 停用前英夫利昔单抗谷浓度较高降低后续抗药抗体和应答丢失风险。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文为回顾性队列研究。
  • 作者指出该发现需前瞻性验证,最好通过有足够把握度的随机对照试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: The benefit of concomitant immunomodulators (thiopurines or methotrexate) in patients with inflammatory bowel disease (IBD) on anti-tumor necrosis factor α (anti-TNF) (infliximab or adalimumab) maintenance therapy is debated. We compared outcomes after immunomodulator withdrawal vs continuation of combination therapy. METHODS: This was a retrospective cohort study in a general hospital and a tertiary referral center. We included adult IBD patients, receiving anti-TNF therapy for ≥4 months, plus an immunomodulator at baseline, between January 1, 2011, and January 1, 2019. The primary endpoints were loss of response (LOR) (ie, anti-TNF discontinuation because of disease activity) and anti-drug antibodies. Adjusted hazard ratios (aHRs) were calculated by mixed-effects Cox regression analysis. RESULTS: We included 614 treatment episodes of combination therapy in 543 individuals, yielding 1664 patient-years of follow-up. The immunomodulator was withdrawn in 296 (48.2%) episodes after 0.9 (interquartile range, 0.6-2.1) years, which was not associated with a higher risk of LOR (aHR, 1.08; 95% confidence interval [CI], 0.72-1.61), although anti-drug antibodies were detected more frequently (aHR, 2.14; 95% CI, 1.17-3.94), compared with continuation. Clinical remission at the time of withdrawal reduced the risk of LOR (aHR, 0.48; 95% CI, 0.25-0.93), while longer duration of combination therapy before withdrawal decreased the risk of anti-drug antibodies (HR per year, 0.56; 95% CI, 0.32-0.91). Higher prewithdrawal infliximab trough levels reduced the subsequent risks of anti-drug antibodies and LOR. Infliximab trough levels were lower after immunomodulator withdrawal (P = .01). CONCLUSIONS: Patients who withdrew the immunomodulator in this retrospective cohort were not at increased risk of LOR within the following 1-2 years, but an increase in anti-drug antibodies was observed. Our findings require prospective validation, preferably in adequately powered randomized controlled trials.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Mahmoud R, Schultheiss HP, Louwers J, et al. Immunomodulator Withdrawal From Anti-TNF Therapy Is Not Associated With Loss of Response in Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. 2022. PMID: 35101632. doi:10.1016/j.cgh.2022.01.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。